Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.
Exploring the companies and themes that make up this emerging and exciting new sector
Red Light Holland Successfully Imports 200 Psilocybin iMicrodose Packs, Sold in The Netherlands, Into Canada Under a Third Health Canada Approved Psilocybin Import Permit To cGMP Laboratory
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
Ketamine Wellness Centers Announces Partnership With The Veterans Administration (VA) in Arizona
Delic Holdings subsidiary, Ketamine Wellness Centers (KWC) announces a partnership with the Veterans Administration to provide ketamine-assisted therapy for veterans with PTSD.
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
Red Light Holland Files International Patent Application for 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data
Red Light Holland submits a new patent application for its microdosing kits.